Medicus Pharma's Developments and Q3 2025 Financials

Medicus Pharma Ltd. has made significant strides in its clinical development programs, particularly for its doxorubicin-containing microneedle array and Teverelix. The company’s advancements include progress in U.S. and UAE for its SkinJect studies, designed to treat basal cell carcinoma non-invasively. In the UK, full regulatory approval was granted to expand its clinical study.

Financially, Medicus Pharma collected $10.4 million from financing and warrants, raising cash reserves to $8.7 million. Operating expenses increased significantly to $15.4 million, largely due to research, general, and administrative costs. The company's net loss rose to $16.0 million as it pursued expansions and acquisitions, including the UK-based Antev Limited.

The acquisition of Antev introduces Teverelix, aimed at prostate cancer patients with cardiovascular risks, to Medicus’s pipeline, potentially carving out a strong market opportunity. Additionally, a collaboration with Helix Nanotechnologies was established to explore vaccine developments.